Company Encyclopedia
View More
name
Dare Bioscience
DARE.US
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies.
4.514 T
DARE.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
E
PharmaceuticalsIndustry
Industry Ranking182/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-2543.13%E
    • Profit Margin30568.80%A
    • Gross Margin100.00%A
  • Growth ScoreD
    • Revenue YoY-103.04%E
    • Net Profit YoY-384.47%E
    • Total Assets YoY70.27%A
    • Net Assets YoY292.52%A
  • Cash ScoreD
    • Cash Flow Margin0.33%D
    • OCF YoY-103.04%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreE
    • Gearing Ratio90.71%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Dare Bioscience Announces Return Of Rights To Ovaprene Phase 3 Program Ongoing Positive Interim Data

    Dare Bioscience Inc :DARÉ BIOSCIENCE ANNOUNCES RETURN OF RIGHTS TO OVAPRENE®; PHASE 3 PROGRAM ONGOING; POSITIVE INTERIM DATA AND GRANT FUNDING POSITION ASSET FOR VALUE-MAXIMIZATIONDARE BIOSCIENCE INC - TERMINATION EFFECTIVE FEBRUARY 2026, DARÉ GAINS FULL CONTROL OF OVAPRENE

    Reuters·
    US
    DARE
    +2.58%
    Reuters·
    US
    DARE
    +2.58%

    Daré Bioscience’s Earnings Call Highlights Growth and Challenges

    Daré Bioscience's Q3 earnings call highlighted significant growth in its commercial and clinical pipeline, supported by strong financial management and strategic partnerships. Key developments include the upcoming launch of DARE to PLAY Sildenafil Cream and advancements in grant-funded programs like Ovaprene and DARE-HPV. Despite challenges such as increased expenses and limited ATM capacity, the company maintains a positive outlook with plans for future product launches and a dual path strategy for commercialization and FDA approval.

    Tip Ranks·
    US
    DARE
    +2.58%
    Tip Ranks·
    US
    DARE
    +2.58%

    Dare Bioscience | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 2.262 K

    LB filings·
    US
    DARE
    +2.58%
    LB filings·
    US
    DARE
    +2.58%

    Dare Bioscience | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 2.262 K

    LB filings·
    US
    DARE
    +2.58%
    LB filings·
    US
    DARE
    +2.58%

    Dare Bioscience Reports Q3 2025 Results and Plans December Launch of Sildenafil Cream

    Daré Bioscience Inc. reported Q3 2025 financial results and announced the December launch of DARE to PLAY™ Sildenafil Cream via the 503B compounding pathway. The company also reported positive interim DSMB results for the Ovaprene® Phase 3 study and advancements in grant-funded programs. Daré plans to commercialize four women's health products over the next two years, including DARE to RESTORE™ vaginal probiotics and DARE to RECLAIM™ hormone therapy. Investors are encouraged to review the company's Form 10-Q for detailed financial information.

    Reuters·
    US
    DARE
    +2.58%
    Reuters·
    US
    DARE
    +2.58%
    © 2025 Longbridge｜Disclaimer